YK Bioventures Opportunities GP I, LLC - Oct 10, 2024 Form 4 Insider Report for CERO THERAPEUTICS HOLDINGS, INC. (CERO)

Role: 10%+ Owner
Signature: YK Bioventures Opportunities GP I, LLC, By /s/ Gary K. Yeung, Managing Partner
Stock symbol: CERO
Transactions as of: Oct 10, 2024
Transactions value $: -$325,000
Form type: 4
Date filed: 11/14/2024, 08:14 PM
Previous filing: Nov 14, 2024
Next filing: Dec 10, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CERO	Common Stock	Sale	-$325K	-3.25M	-12.56%	$0.10	22.6M	Oct 10, 2024	By YK Bioventures Opportunities Fund I, L.P.	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $0.09 to $0.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F2	Securities are held directly by YK Bioventures Opportunities Fund I, L.P. (f/k/a YK Bioventures, LLC) ("YK Opps I"). YK Bioventures Opportunities GP I, LLC ("YK Opps I GP") is the general partner of YK Opps I and may be deemed to beneficially own the shares held by YK Opps I. Mitchell W. Kossar and Gary K. Yeung are managing partners of YK Opps I GP, and may be deemed to share voting and investment power over the shares held by YK Opps I. Each of YK Opps I GP and Messrs. Kossar and Yeung disclaims beneficial ownership of these shares except to the extent of its or his respective pecuniary interest therein.

Content

The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $0.09 to $0.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Securities are held directly by YK Bioventures Opportunities Fund I, L.P. (f/k/a YK Bioventures, LLC) ("YK Opps I"). YK Bioventures Opportunities GP I, LLC ("YK Opps I GP") is the general partner of YK Opps I and may be deemed to beneficially own the shares held by YK Opps I. Mitchell W. Kossar and Gary K. Yeung are managing partners of YK Opps I GP, and may be deemed to share voting and investment power over the shares held by YK Opps I. Each of YK Opps I GP and Messrs. Kossar and Yeung disclaims beneficial ownership of these shares except to the extent of its or his respective pecuniary interest therein.